Treatment
Proposal for a new local recurrence score in patients with recurrent malignant pleural mesothelioma
Journal of Thoracic Disease 2022 August [Link] Olivia Lauk, Thomas Neuer, Bianca Battilana, Ilhan Inci, Katarzyna Furrer, Walter Weder, Masaki Hashimoto, Isabelle Opitz Abstract Background: Malignant pleural mesothelioma (MPM) is associated with high rates of local recurrence (LR) up to 75%. Second line treatment should be applied tailored to relapse pattern. We aimed to establish…
Read MoreBrief Report: Multimodality Therapy in Patients with Primary Pericardial Mesothelioma
Journal of Thoracic Oncology 2022 September 5 [Link] Michael Offin, Dilanka De Silva, Jennifer L Sauter, Jacklynn V Egger, Ellen Yorke, Prasad S Adusumilli, Andreas Rimner, Valerie W Rusch, Marjorie G Zauderer Abstract Background: Primary pericardial mesothelioma (PPM) has no accepted standard of care treatment options with management and outcomes often extrapolated from diffuse pleural…
Read MoreSurvival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma
Journal of Chest Surgery 2022 September 7 [Link] Muhammet Sayan, Aynur Bas, Merve Satir Turk, Dilvin Ozkan, Ali Celik, İsmail Cuneyt Kurul, Abdullah Irfan Tastepe Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, and despite all multimodal treatment modalities, the 5-year overall survival rate of patients with MPM is less than 20%.…
Read MoreMeta-analysis of survival after extrapleural pneumonectomy (EPP) versus pleurectomy/decortication (P/D) for malignant pleural mesothelioma in the context of macroscopic complete resection (MCR)
Updates in Surgery 2022 September 3 [Link] Dimitrios E Magouliotis, Prokopis-Andreas Zotos, Arian Arjomandi Rad, Despoina Koukousaki, Vasiliki Vasilaki, Ioustini Portesi, Kyriakos Spiliopoulos, Thanos Athanasiou Abstract Objective: We reviewed the available literature on patients with MPM undergoing either extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D). Methods: Original research studies that evaluated long-term outcomes of P/D versus…
Read MoreA trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) – a randomised feasibility study using the trial within a cohort (TwiC) methodology
Pilot & Feasibility Studies 2022 September 3 [Link] Anna C Bibby, Natalie Zahan-Evans, Emma Keenan, Charles Comins, John E Harvey, Helen Day, Najib M Rahman, Janet E Fallon, Rachael Gooberman-Hill, Nick A Maskell Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive thoracic malignancy with a poor prognosis. Systemic immunotherapy is an effective frontline treatment…
Read MoreFeasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience
Thoracic Cancer 2022 September 2 [Link] Francesco Falanga, Pietro Rinaldi, Cristiano Primiceri, Chandra Bortolotto, Olga Oneta, Francesco Agustoni, Patrizia Morbini, Laura Saracino, Dimitrios Eleftheriou, Federico Sottotetti, Giulia Maria Stella Abstract Surgery is part of a multimodal therapeutic approach to malignant pleural mesothelioma (MPM) although its real beneficial effect is still controversial. The optimal precise sequence…
Read MoreIL-7 is expressed in malignant mesothelioma and has a prognostic value
Molecular Oncology 2022 August 28 [Link] Hoa-Le Mai, Sophie Deshayes, Thi-Van-Ha Nguyen, Virginie Dehame, Anne-Laure Chéné, Sophie Brouard, Christophe Blanquart Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer mainly related to asbestos exposure. Despite recent therapeutic advances, notably immunotherapies, the benefit remains limited and restricted to a small percentage of patients. Thus, a better…
Read MorePrognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma
Cancer Medicine 2022 August 28 [Link] Yue Jiang, Chengda Zhang, Yang Chen, Shiyu Zhao, Yipeng He, Jun He Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and highly malignant thoracic tumor. Although alternative splicing (AS) is associated with tumor prognosis, the prognostic significance of AS in MPM is unknown. Methods: Transcriptomic data, clinical information,…
Read MoreTraining and validation of a knowledge-based dose-volume histogram predictive model in the optimisation of intensity-modulated proton and volumetric modulated arc photon plans for pleural mesothelioma patients
Radiation Oncology 2022 August 26 [Link] Davide Franceschini, Luca Cozzi, Antonella Fogliata, Beatrice Marini, Luciana Di Cristina, Luca Dominici, Ruggero Spoto, Ciro Franzese, Pierina Navarria, Tiziana Comito, Giacomo Reggiori, Stefano Tomatis, Marta Scorsetti Abstract Background: To investigate the performance of a narrow-scope knowledge-based RapidPlan (RP) model for optimisation of intensity-modulated proton therapy (IMPT) and volumetric…
Read MoreActivation of adaptive and innate immune cells via localized Interleukin-2 cytokine factories eradicates mesothelioma tumors
Clinical Cancer Research 2022 August 22 [Link] Amanda M Nash, Samira Aghlara-Fotovat, Bertha Castillio, Andrea Hernandez, Aarthi Pugazenthi, Hyun-Sung Lee, Hee-Jin Jang, Annie Nguyen, Alexander Lu, Bryan M Burt, Ravi K Ghanta, Omid Veiseh Abstract Purpose: Interleukin-2 (IL-2) immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical…
Read More